1,390 Shares in Enanta Pharmaceuticals Inc (ENTA) Purchased by SG Americas Securities LLC

SG Americas Securities LLC bought a new stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,390 shares of the biotechnology company’s stock, valued at approximately $112,000.

Other institutional investors have also added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership bought a new position in Enanta Pharmaceuticals in the fourth quarter valued at about $1,191,000. BlackRock Inc. grew its holdings in shares of Enanta Pharmaceuticals by 4.3% during the fourth quarter. BlackRock Inc. now owns 2,343,593 shares of the biotechnology company’s stock worth $137,521,000 after purchasing an additional 97,054 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Enanta Pharmaceuticals by 13.3% during the fourth quarter. Renaissance Technologies LLC now owns 771,600 shares of the biotechnology company’s stock worth $45,277,000 after purchasing an additional 90,500 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Enanta Pharmaceuticals by 34.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 8,300 shares of the biotechnology company’s stock worth $487,000 after purchasing an additional 2,130 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $286,000. Hedge funds and other institutional investors own 76.21% of the company’s stock.

NASDAQ:ENTA opened at $114.02 on Tuesday. The stock has a market cap of $2.22 billion, a PE ratio of 125.30 and a beta of 1.07. Enanta Pharmaceuticals Inc has a 1-year low of $33.15 and a 1-year high of $122.43.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported $0.61 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.08. The company had revenue of $44.00 million for the quarter, compared to the consensus estimate of $40.77 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. Enanta Pharmaceuticals’s revenue was up 388.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.28) earnings per share. research analysts anticipate that Enanta Pharmaceuticals Inc will post 3.36 EPS for the current year.

Several research firms have recently weighed in on ENTA. Oppenheimer began coverage on Enanta Pharmaceuticals in a report on Thursday, June 7th. They set a “buy” rating and a $135.00 price target on the stock. BidaskClub cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $111.00 price target on the stock in a report on Thursday, May 3rd. Roth Capital began coverage on Enanta Pharmaceuticals in a report on Wednesday, June 6th. They set a “buy” rating and a $133.00 price target on the stock. Finally, Royal Bank of Canada restated a “hold” rating and set a $80.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, April 4th. Four analysts have rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $83.71.

In other Enanta Pharmaceuticals news, Treasurer Paul J. Mellett sold 15,000 shares of the stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $120.57, for a total transaction of $1,808,550.00. Following the transaction, the treasurer now owns 88,158 shares of the company’s stock, valued at $10,629,210.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Nathalie Adda sold 4,225 shares of the stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $85.58, for a total transaction of $361,575.50. Following the transaction, the vice president now directly owns 10,225 shares in the company, valued at approximately $875,055.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,380 shares of company stock worth $5,253,189. 10.56% of the stock is currently owned by insiders.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply